Insider Transactions in Q1 2024 at Edwards Lifesciences Corp (EW)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
14,500
-26.85%
|
$1,319,500
$91.01 P/Share
|
|
Mar 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
14,500
+21.17%
|
$522,000
$36.75 P/Share
|
|
Mar 11
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Open market or private sale
|
Direct |
14,400
-7.66%
|
$1,310,400
$91.68 P/Share
|
|
Mar 11
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
14,400
+7.12%
|
$518,400
$36.75 P/Share
|
|
Mar 07
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
1,715
-9.06%
|
$154,350
$90.98 P/Share
|
|
Mar 07
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,715
+8.31%
|
$61,740
$36.75 P/Share
|
|
Mar 04
2024
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-58.74%
|
$2,524,100
$86.63 P/Share
|
|
Mar 04
2024
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|
|
Feb 29
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.56%
|
$616,675
$85.59 P/Share
|
|
Feb 29
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.6%
|
$261,180
$36.75 P/Share
|
|
Feb 23
2024
|
Kieran Gallahue Director |
SELL
Open market or private sale
|
Indirect |
3,058
-4.35%
|
$266,046
$87.61 P/Share
|
|
Feb 23
2024
|
Kieran Gallahue Director |
BUY
Bona fide gift
|
Indirect |
7,056
+9.12%
|
-
|
|
Feb 23
2024
|
Kieran Gallahue Director |
SELL
Bona fide gift
|
Direct |
7,056
-65.59%
|
-
|
|
Feb 23
2024
|
Kieran Gallahue Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,056
+39.61%
|
$254,016
$36.86 P/Share
|
|
Feb 22
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
8,560
+16.48%
|
-
|
|
Feb 22
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,998
+11.7%
|
-
|
|
Feb 21
2024
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
8,200
-13.7%
|
$705,200
$86.71 P/Share
|
|
Feb 21
2024
|
Daveen Chopra CVP, TMTT |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+18.45%
|
$413,000
$59.26 P/Share
|
|
Feb 18
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-1.08%
|
$16,168
$86.1 P/Share
|
|
Feb 17
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
150
-0.85%
|
$12,900
$86.1 P/Share
|
|
Feb 16
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
207
-1.17%
|
$17,802
$86.04 P/Share
|
|
Feb 16
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-0.15%
|
$27,262
$86.04 P/Share
|
|
Feb 16
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.9%
|
$14,964
$86.04 P/Share
|
|
Feb 15
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
27,000
-43.68%
|
$2,295,000
$85.62 P/Share
|
|
Feb 15
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+30.4%
|
$972,000
$36.75 P/Share
|
|
Feb 13
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
20,000
-36.49%
|
$1,720,000
$86.46 P/Share
|
|
Feb 13
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+26.73%
|
$720,000
$36.75 P/Share
|
|
Feb 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
11,000
-10.99%
|
$946,000
$86.08 P/Share
|
|
Feb 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+17.89%
|
$396,000
$36.75 P/Share
|
|
Feb 12
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Open market or private sale
|
Direct |
12,210
-48.27%
|
$1,062,270
$87.0 P/Share
|
|
Feb 12
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,210
+32.55%
|
$439,560
$36.75 P/Share
|
|
Feb 08
2024
|
Heisz Leslie Stone Director |
SELL
Open market or private sale
|
Direct |
7,056
-20.73%
|
$606,816
$86.45 P/Share
|
|
Feb 08
2024
|
Heisz Leslie Stone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,056
+17.17%
|
$254,016
$36.86 P/Share
|
|
Feb 05
2024
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-33.13%
|
$2,582,800
$88.06 P/Share
|
|
Feb 05
2024
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|
|
Feb 01
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.37%
|
$565,890
$78.29 P/Share
|
|
Feb 01
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.49%
|
$261,180
$36.75 P/Share
|
|
Jan 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
10,000
-20.2%
|
$750,000
$75.67 P/Share
|
|
Jan 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.81%
|
$360,000
$36.75 P/Share
|
|
Jan 05
2024
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-46.54%
|
$2,142,550
$73.2 P/Share
|
|
Jan 05
2024
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|